66737-88-0

Usage

Uses

Used in Oxidative Stress Research:
3-TERT-BUTYL-4-HYDROXYBENZOIC ACID is used as an antioxidant in oxidative stress research for its ability to counteract the harmful effects of reactive oxygen species, which are involved in various diseases and aging processes.
Used in Pharmaceutical Design and Synthesis:
3-TERT-BUTYL-4-HYDROXYBENZOIC ACID is used as a key component in the design and synthesis of pharmaceuticals and natural product-like compounds, contributing to the development of new drugs and therapeutic agents.
Used in Chemical Compounds:
3-TERT-BUTYL-4-HYDROXYBENZOIC ACID is used as a chemical compound in the Benzoic acids and derivatives class, which is essential for various chemical reactions and processes in the chemical industry.

Upstream product

• 39778-63-7 3-(1,1-dimethylethyl)-4-hydroxybenzoic acid methyl ester 
• 66737-89-1 3-(tert-butyl)-4-methoxybenzoic acid 
• 4910-04-7 3-(1,1-dimethylethyl)-4-hydroxybenzonitrile 
• 1421-49-4 3,5-Di-tert-butyl-4-hydroxybenzoic acid 
• 150094-87-4 2-tert-butyl-1-methoxymethoxy-4-methylbenzene 
• 2409-55-4 2-tert-Butyl-4-methylphenol 
• 10323-39-4 4-bromo-2-tert-butylphenol 
• 88-18-6 2-tert-Butylphenol 

Downstream Products

• 147219-64-5 3-(1,1-dimethylethyl)-4-<<(1,1-dimethylethyl)dimethylsilyl>oxy>benzoic acid (1,1-dimethylethyl)dimethylsilyl ester 
• 125182-27-6 methyl 3-tert-butyl-4-methoxybenzoate 
• 847943-49-1 3-tert-butyl-4-hydroxy-benzoic acid tert-butyl ester 
• 39778-63-7 3-(1,1-dimethylethyl)-4-hydroxybenzoic acid methyl ester 
• 912999-00-9 (3-tert-butyl-4-hydroxy-phenyl)-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-methanone 
• 912998-96-0 (3-tert-butyl-4-hydroxy-phenyl)-(2,3-dihydro-indol-1-yl)-methanone 
• 912544-63-9 1-(3-tert-butyl-4-hydroxybenzoyl)-4-hydroxypiperidine 
• 912544-60-6 4-acetyl-1-(3-tert-butyl-4-hydroxybenzoyl)piperazine 
• 912544-65-1 1-(3-tert-butyl-4-hydroxybenzoyl)-4-(2-pyridyl)piperazine 
• 882500-52-9 3-(tert-butyl)-5-formyl-4-hydroxybenzoic acid 
• 882500-53-0 methyl-3-tert-butyl-5-formyl-4-hydroxybenzoate 
• 912999-01-0 2-(3-tert-butyl-4-hydroxybenzoyl)-2,3-dihydro-1H-isoindole 
• 628337-20-2 1-(6-benzyloxy-5-tert-butyl-4'-methyl-3-biphenylyl)prop-2-yn-1-ol 
• 628337-18-8 methyl 6-benzyloxy-5-tert-butyl-4'-methyl-3-biphenylcarboxylate 

Relevant academic research and scientific papers

Novel benzofuran derivative as well as preparation method and application thereof

The invention belongs to the field of medicines, and in particular relates to a novel benzofuran derivative or a pharmaceutical salt thereof, a preparation method of the derivative, a medicinal composition containing the derivative, and application of the

Nano- and microcrystals of a Mn-based metal-oligomer framework showing size-dependent magnetic resonance behaviors

A robust 3D Mn-based metal-organic framework containing metallosalen hexamers is synthesized and its nano- and microcrystals are fabricated by using surfactant-mediated hydrothermal and solvent precipitation methods; the particles exhibit an inverse size-

Isoreticular chiral metal-organic frameworks for asymmetric alkene epoxidation: Tuning catalytic activity by controlling framework catenation and varying open channel sizes

A family of isoreticular chiral metal-organic frameworks (CMOFs) of the primitive cubic network topology was constructed from [Zn4(μ 4-O)(O2CR)6] secondary building units and systematically elongated dicarboxyla

BICYCLIC COMPOUNDS USEFUL AS CATHEPSIN S INBHIBITORS

Compounds of formula (I), wherein R1, R2, R3, Ra and E are are defined within, and pharmaceutically acceptable salts, solvates, hydrates and N-oxides thereof having utility in the treatment of disorders mediated by cathepsin S.

Discovery, structure - Activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors

A series of (5-substituted pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidine (C5-Pro-Pro) analogues was discovered as dipeptidyl peptidase IV (DPPIV) inhibitors as a potential treatment of diabetes and obesity. X-ray crystallography data show that these inhibitors bind to the catalytic site of DPPIV with the cyano group forming a covalent bond with the serine residue of DPPIV. The C5-substituents make various interactions with the enzyme and affect potency, chemical stability, selectivity, and PK properties of the inhibitors. Optimized analogues are extremely potent with subnanomolar Ki's, are chemically stable, show very little potency decrease in the presence of plasma, and exhibit more than 1,000-fold selectivity against related peptidases. The best compounds also possess good PK and are efficacious in lowering blood glucose in an oral glucose tolerance test in ZDF rats.

CATHEPSIN S INHIBITORS

Compounds of the formula (I) where R1 is C1-C4 straight or branched alkyl, optionally substituted with up to three substituents selected from halo and hydroxy; R2 is halo, hydroxy, methyloxy, or C1-C2 alkyl, which alkyl is optionally substituted with up to three halogens or an hydroxy or a methyloxy; D is - C3-C7 alkylene-, thereby defining a cycloalkyl ring; E is -C(=O)-, -S(=O)m-, -NRdS(=O)m-, -NRaC(=O)-, -OC(=O)-, R3 is an optionally substituted carbocyclic or heterocyclic ring R10 is H, ORc, SRc or together with the gem H is =O or (ORc)2; Ra is independently selected from H, C1-C4 alkyl; have utility in the inhibition of cathepsin S and are thus useful pharmaceuticals against disorders such as autoimmune disorders and chronic pain.